<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="176114">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00802919</url>
  </required_header>
  <id_info>
    <org_study_id>081/C02</org_study_id>
    <secondary_id>FDA IND 102,411</secondary_id>
    <nct_id>NCT00802919</nct_id>
  </id_info>
  <brief_title>Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors</brief_title>
  <official_title>Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors, Independent Investigator Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nathan Kline Institute for Psychiatric Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nathan Kline Institute for Psychiatric Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12-week double-blind placebo controlled parallel group study of the efficacy of
      varenicline (Chantix) for smoking cessation in schizophrenic patients, and its effect on
      cognitive function in patients with schizophrenia. Correlations will be made with biological
      predictors of efficacy: a) measures of nicotinic receptors in lymphocytes b) DNMT1 and GAD67
      mRNA in lymphocytes. Subjects will be current cigarette smokers or hsitory of regular
      smokers.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cotinine Level</measure>
    <time_frame>monthly</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Scores on MATRICS Neuropsychological Battery</measure>
    <time_frame>baseline and end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PANSS Total Score</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calgary Depression Scale Score</measure>
    <time_frame>baseline and monthly</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Cigarette Smoking</condition>
  <arm_group>
    <arm_group_label>Varenicline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Varenciline 1-2 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo for varenicline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Varenicline 1-2 mg/day</description>
    <arm_group_label>Varenicline</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for varenicline</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Matched Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diagnosis of Schizophrenia or Schizoaffective Disorder Current Cigarette Smoker Age 18-65
        Currently taking antipsychotic medication

        Exclusion Criteria:

        prior history of hospitalization for acute myocardial infarction or stroke, or persistent
        angina pectoris with current symptoms Patients who have previously tried varenicline and
        have stopped taking it because of side-effects of severe nausea or vomiting suicide
        attempt in the last year and or have had prominent or serious suicidal thoughts in the
        past year Women who are pregnant, nursing, or unable to use reliable contraception
        significant renal impairment(Creatinine â‰¥ 1.5) baseline Hamilton Depression Scores is &gt;20
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert C. Smith, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Manhattan Psychiatric Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Manhattan Psychatirc Center</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Nathan Kline Insitute for Psychiatric Research</name>
      <address>
        <city>Orangeburg,</city>
        <state>New York</state>
        <zip>10962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence Maayan, MD</last_name>
      <phone>845-398-6637</phone>
      <email>lmaayan@nki.rfmh.org</email>
    </contact>
    <contact_backup>
      <last_name>Robert C smith, MD PhD</last_name>
      <phone>845-398-6531</phone>
      <email>rsmith@nki.rfmh.org</email>
    </contact_backup>
    <investigator>
      <last_name>Lawrence Maayan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Division of Psychiatry, Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Revital Amiaz, MD</last_name>
      <phone>+972-3-530-3774</phone>
      <email>revital.amiaz@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Revital Amiaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <lastchanged_date>May 16, 2012</lastchanged_date>
  <firstreceived_date>December 4, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nathan Kline Institute for Psychiatric Research</investigator_affiliation>
    <investigator_full_name>Robert C. Smith MD PhD</investigator_full_name>
    <investigator_title>Research Psychiatrist, Principal Investigagtor</investigator_title>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>smoking</keyword>
  <keyword>nicotine</keyword>
  <keyword>cognitive deficits</keyword>
  <keyword>DNMT1 mRNA</keyword>
  <keyword>nicotinic receptors</keyword>
  <keyword>Cognitive Deficits in Schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
